RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
AIM ImmunoTech (NYSEMKT:AIM) +45% pre-market after saying it has joined with ChinaGoAbroad to facilitate the entry of its experimental drug Ampligen into China for use as an early-onset therapeutic against COVID-19.
ChinaGoAbroad is a member-based online information platform serving to facilitate two-way international transactions in collaboration with the China Overseas Development Association.
AIM says Ampligen achieved a 100% survival rate in SARS animal experiments after the 2003 outbreak, and it believes the drug may provide similarly effective prophylaxis against COVID-19.
Forty Seven Inc. (NASDAQ:FTSV) +23% after-hours following a Bloomberg report that Gilead Sciences (NASDAQ:GILD) has approached the company with a takeover offer.
Gilead and Forty Seven are discussing several of options including a partnership, according to the report, which adds that Forty Seven also has received interest from other potential suitors.
Forty Seven is working on cancer treatments that harness the immune system to fight tumors.
Sangamo Therapeutics (NASDAQ:SGMO) is up 39.4% after hours following the signing of a gene therapy deal with Biogen (NASDAQ:BIIB).
The two have agreed on broad collaboration for gene therapies in neurology, with an initial focus on ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target.
The deal also has exclusive rights for nine additional, undisclosed neurological targets.
Biogen will pay Sangamo $350M up front, including license fees and equity investment in Sangamo stock, and Sangamo is eligible to get up to $2.37B in potential milestones along with royalties on potential commercial sales.
LivaNova (LIVN +12.1%) shares surged after Reorg Research reported that Medtronic (MDT -3.8%) is in early stage talks to acquire the company.
Medtronic was pitched recently on acquiring LivaNova, and the proposal has gained traction, according to the report.
Biohaven Pharmaceuticals (NYSE:BHVN) +7.8% after-hours on news the Food and Drug Administration approved its Nurtec ODT (rimegepant) for the acute treatment of migraine in adults.
The company says a single 75 mg oral dose of the pill can provide fast pain relief, return patients to normal function within one hour and deliver sustained efficacy that lasts up to 48 hours for many patients.
Biohaven hopes rimegepant’s oral use and its dual applicatio will help it stand out from rival drugs, as most other calcitonin gene-related peptide inhibitors approved for migraine prevention are administered by injections.
